Karyopharm Therapeutics
343 articles about Karyopharm Therapeutics
-
Karyopharm Reports Strong Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
2/8/2022
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm," the "Company," "we" and "our"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Karyopharm Announces Phase 3 SIENDO Study Meets Primary Endpoint with Statistically Significant Increase in Progression-Free Survival in Patients with Advanced or Recurrent Endometrial Cancer
2/8/2022
Karyopharm Therapeutics Inc. today announced positive top-line results from the Phase 3 Selinexor In ENDOmetrial Cancer.
-
Karyopharm to Report Fourth Quarter and Full Year 2021 Financial Results on February 8, 2022
2/2/2022
Karyopharm Therapeutics Inc. today announced it will report fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2022
2/1/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 124,500 shares of Karyopharm's common stock to 15 newly-hired employees, with a grant date of January 31, 2022.
-
Karyopharm Receives Orphan Drug Designation from FDA for Eltanexor for the Treatment of Myelodysplastic Syndromes
1/24/2022
Karyopharm Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for eltanexor.
-
Karyopharm to Present at B. Riley Securities Oncology Investor Conference
1/21/2022
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will present virtually at the B. Riley Securities Oncology Investor Conference.
-
Karyopharm Promotes Sohanya Cheng to Chief Commercial Officer
1/10/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that Sohanya Cheng has been promoted to Chief Commercial Officer.
-
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives
1/10/2022
Karyopharm Therapeutics Inc. announced preliminary unaudited fourth quarter and full year 2021 net product revenue estimates for XPOVIO, the Company's first-in-class, oral XPO1 inhibitor, and outlined its 2021 achievements and 2022 objectives.
-
Karyopharm to Present at 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Karyopharm Therapeutics Inc. today announced that Richard Paulson , President and Chief Executive Officer of Karyopharm, will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 03, 2022
1/3/2022
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 5,600 shares of Karyopharm's common stock to 2 newly-hired employees, with a grant date of December 31, 2021.
-
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO® (selinexor) in Europe and Other Key Global Territories
12/21/2021
Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic and Solid Tumor Oncology Indications in Europe (including the United Kingdom), Latin America and Other Key Countries.
-
Karyopharm's Partner Antengene Receives Approval in China for XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
12/17/2021
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner, Antengene Corporation (Antengene), has been granted conditional approval for marketing by the China National Medical Products Administration (NMPA) for XPOVIO® (selinexor).
-
Karyopharm Announces Presentation of Updated Phase 2 Selinexor Data in Patients with Myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
12/11/2021
Karyopharm Therapeutics Inc. announced an oral presentation highlighting updated data from the Phase 2 ESSENTIAL study, an investigator-sponsored study evaluating single-agent selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export compound, in patients with myelofibrosis previously treated with JAK inhibition.
-
Karyopharm Announces the Appointment of Peter K Honig, MD, MPH to its Board of Directors
12/6/2021
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021.
-
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis
12/6/2021
Karyopharm Therapeutics Inc. today announced dosing of the first patient in a new Phase 2 study evaluating oral selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a monotherapy versus physician's choice in patients with myelofibrosis (MF) previously treated with a JAK 1/2 inhibitor (XPORT-MF-035; NCT04562870).
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
Karyopharm Completes Patient Recruitment in Phase 3 SIENDO Study of Selinexor in Patients with Endometrial Cancer
12/2/2021
Karyopharm Therapeutics Inc. today announced the completion of patient recruitment in the Phase 3 SIENDO study evaluating the efficacy and safety for front-line maintenance therapy with selinexor in patients with advanced or recurrent endometrial cancer.
-
Karyopharm to Host Virtual Investor Day on December 8, 2021
12/1/2021
Karyopharm Therapeutics Inc. today announced it will host a virtual Investor Day on Wednesday, December 8, 2021 from 10:00 a.m. to 12:30 p.m. ET.
-
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2021
12/1/2021
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 68,900 shares of Karyopharm's common stock to 13 newly-hired employees, with a grant date of November 30, 2021.
-
Karyopharm to Participate at Jefferies London Healthcare Conference
11/11/2021
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the Jefferies London Healthcare Conference.